Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases - PubMed (original) (raw)
Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases
Farbod Darvishian et al. Am J Surg Pathol. 2004 Dec.
Abstract
Background: Uterine serous carcinomas (USCs) can exhibit an architecturally well-differentiated tubuloglandular morphology with or without an accompanying papillary growth pattern. These features make it difficult to distinguish USCs from endometrial endometrioid carcinomas (EECs). Given the aggressive behavior of USC, compared with EEC, and differences in management, it is important to correctly classify endometrial carcinomas that exhibit a tubuloglandular architecture with high nuclear grade. We sought an immunohistochemical panel to minimize subjectivity in the distinction of USC from EEC.
Materials and methods: We identified 8 problematic endometrial cancers, exhibiting a tubuloglandular growth pattern and high nuclear grade, whose classification as EEC or USC was debated or resulted in disagreement. We selected 13 cases of International Federation of Gynecology and Obstetrics (FIGO) grade 2 EEC and 16 cases of USC as controls. An immunohistochemical panel, including p53, beta-catenin, cyclin D1, estrogen receptor (ER), progesterone receptor (PR), and PTEN, was evaluated.
Results: As a group, the clinical features and immunoprofile of the study cases resembled those of the serous controls. The study cases expressed p53, beta-catenin, cyclin D1, and ER and PR, and showed loss of PTEN in 75%, 12.5%, 0%, 37.5%, 37.5%, and 12.5% of cases, respectively. p53, beta-catenin, cyclin D1, ER and PR expression, and PTEN loss were seen in 87.5%, 0%, 19%, 31%, 12%, and 0% of the serous controls and in 7%, 70%, 54%, 92%, 92%, and 61.5% of the endometrioid controls, respectively. The combination of lack of p53 expression, positive PR expression, and loss of PTEN best distinguished between EEC and USC using discriminant analysis (multivariate P = 0.008, <0.001, and 0.05, respectively).
Conclusion: In endometrial carcinomas exhibiting high nuclear grade and low architectural grade, using a panel of immunohistochemical stains may facilitate the distinction of USC from EEC. Our clinical and immunohistochemical data also support the concept that there is a group of endometrial adenocarcinomas composed of tubular glands that are indeed serous carcinomas.
Similar articles
- Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A, Ji H, Shih IeM, Wang TL, Wu LS, Ronnett BM. Yemelyanova A, et al. Am J Surg Pathol. 2009 Oct;33(10):1504-14. doi: 10.1097/PAS.0b013e3181ac35f5. Am J Surg Pathol. 2009. PMID: 19623034 - Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis.
Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Reid-Nicholson M, et al. Mod Pathol. 2006 Aug;19(8):1091-100. doi: 10.1038/modpathol.3800620. Epub 2006 Apr 28. Mod Pathol. 2006. PMID: 16648864 - Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ, Lee YH, Cho NH, Shim JY, Kim JY, Lee C, Kim SJ. An HJ, et al. Histopathology. 2002 Nov;41(5):437-45. doi: 10.1046/j.1365-2559.2002.01455.x. Histopathology. 2002. PMID: 12405911 - High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.
Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, Irving JA, Malpica A, Matias-Guiu X, McCluggage WG, Mittal K, Oliva E, Parkash V, Rutgers JKL, Staats PN, Stewart CJR, Tornos C, Soslow RA. Murali R, et al. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1(Iss 1 Suppl 1):S40-S63. doi: 10.1097/PGP.0000000000000491. Int J Gynecol Pathol. 2019. PMID: 30550483 Free PMC article. Review. - A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF, Kurman RJ. Lax SF, et al. Verh Dtsch Ges Pathol. 1997;81:228-32. Verh Dtsch Ges Pathol. 1997. PMID: 9474874 Review.
Cited by
- Trends in the incidence and survival outcomes of endometrial cancer in Korea: a nationwide population-based cohort study.
Shim SH, Lim J, Kim JH, Lee YJ, Ha HI, Lim MC, Won YJ. Shim SH, et al. J Gynecol Oncol. 2024 May;35(3):e32. doi: 10.3802/jgo.2024.35.e32. Epub 2023 Dec 19. J Gynecol Oncol. 2024. PMID: 38130136 Free PMC article. - Predicting endometrial cancer subtypes and molecular features from histopathology images using multi-resolution deep learning models.
Hong R, Liu W, DeLair D, Razavian N, Fenyö D. Hong R, et al. Cell Rep Med. 2021 Sep 23;2(9):100400. doi: 10.1016/j.xcrm.2021.100400. eCollection 2021 Sep 21. Cell Rep Med. 2021. PMID: 34622237 Free PMC article. - Fertility-Sparing Treatment for Atypical Endometrial Hyperplasia and Endometrial Cancer: A Cochrane Systematic Review Protocol.
Fernandez-Montoli ME, Sabadell J, Contreras-Perez NA. Fernandez-Montoli ME, et al. Adv Ther. 2021 May;38(5):2717-2731. doi: 10.1007/s12325-021-01693-y. Epub 2021 Apr 8. Adv Ther. 2021. PMID: 33830463 - The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
Hagemann IS, Deng W, Zaino RJ, Powell MA, Gunderson C, Cosgrove C, Mathews C, Pearl ML, Waggoner S, Ghebre R, Lele S, Guntupalli S, Secord AA, Ioffe O, Park K, Rasty G, Singh M, Soslow R, Creasman W, Mutch DG. Hagemann IS, et al. Gynecol Oncol. 2021 Mar;160(3):660-668. doi: 10.1016/j.ygyno.2020.12.040. Epub 2021 Jan 8. Gynecol Oncol. 2021. PMID: 33423806 Free PMC article. - Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma.
Dessources K, Da Cruz Paula A, Pareja F, Stylianou A, Cybulska P, Farmanbar A, Chandarlapaty S, Abu-Rustum NR, Reis-Filho JS, Weigelt B, Mueller JJ. Dessources K, et al. JCO Precis Oncol. 2020 Oct 5;4:PO.20.00044. doi: 10.1200/PO.20.00044. eCollection 2020. JCO Precis Oncol. 2020. PMID: 33163849 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous